OverviewSuggest Edit

Vanda Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. The Company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorder, and Fanapt (iloperidone), a product for the treatment of schizophrenia. The Company also has several clinical development products.

HQWashington, US
Employee Ratings2.5

Latest Updates

Employees (est.) (Dec 2019)284(+6%)
Job Openings34
Revenue (FY, 2019)$227.2 M(+18%)
Share Price (Sept 2020)$9.4
Cybersecurity ratingCMore

Key People/Management at Vanda Pharmaceuticals

Michael F. Cola

Michael F. Cola

Phaedra Chrousos

Phaedra Chrousos

Anne Sempowski Ward

Anne Sempowski Ward

Mihael H. Polymeropoulos

Mihael H. Polymeropoulos

President and Chief Executive Officer
Aj Jones

Aj Jones

Chief Corporate Affairs and Communications Officer
Gunther Birznieks

Gunther Birznieks

Senior Vice President, Business Development
Show more

Vanda Pharmaceuticals Office Locations

Vanda Pharmaceuticals has offices in Washington, Berlin and London
Washington, US (HQ)
The Avenue, 2200 Pennsylvania Ave NW #300E
Berlin, DE
Französische Straße 12 c/o Satellite Office
London, GB
Tower 42, 21st Floor, 21A 25 Old Broad Street
Show all (3)

Vanda Pharmaceuticals Financials and Metrics

Vanda Pharmaceuticals Revenue

Vanda Pharmaceuticals's revenue was reported to be $227.19 m in FY, 2019

Revenue (Q2, 2020)


Net income (Q2, 2020)


EBIT (Q2, 2020)


Market capitalization (22-Sept-2020)


Closing stock price (22-Sept-2020)


Cash (30-Jun-2020)



Vanda Pharmaceuticals's current market capitalization is $513.7 m.
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019



Cost of goods sold


Gross profit


Gross profit Margin, %

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020



Cost of goods sold


Gross profit


Gross profit Margin, %

USDQ2, 2011

Financial Leverage

5.1 x
Show all financial metrics

Vanda Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Vanda Pharmaceuticals Online and Social Media Presence

Embed Graph

Vanda Pharmaceuticals News and Updates

Vanda Pharmaceuticals CEO's Proposal on Clinical Trial Data Sharing, COVID-19 and Remdesivir

WASHINGTON, May 20, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today released a letter (below) from Mihael H. Polymeropoulos, M.D., President and CEO of Vanda Pharmaceuticals, proposing an approach to Clinical Trial Data Sharing in order to facilitate discovery...

Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia

WASHINGTON, April 2, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced the initiation of clinical study, ODYSSEY VLY-686-3501, in hospitalized patients with COVID-19. The novel SARS-CoV-2 coronavirus is associated with a lower respiratory tract...

Vanda Pharmaceuticals Comments on Court Ruling

WASHINGTON, Jan. 31, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) makes the following statement regarding U.S. District Court case 19-cv-30; U.S. Food and Drug Administration (FDA) v. Vanda, in which the U.S. District Court for the District of Columbia ruled in...

Vanda Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

WASHINGTON, June 18, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that it will deliver a corporate presentation at the JMP Securities Life Sciences Conference in New York City on Wednesday, June 19, 2019 at 2:00 p.m. Eastern Time. The corporate...

Vanda Pharmaceuticals Appoints Phaedra Chrousos to Board of Directors

WASHINGTON, April 24, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that Phaedra Chrousos has joined Vanda's Board of Directors, effective April 23, 2019. Following Ms. Chrousos' appointment, Vanda's Board of Directors is now comprised of six...

Vanda Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019

WASHINGTON, April 18, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2019 on Wednesday, May 1, 2019, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, May 1, 2019,...
Show more

Vanda Pharmaceuticals Frequently Asked Questions

  • When was Vanda Pharmaceuticals founded?

    Vanda Pharmaceuticals was founded in 2002.

  • Who are Vanda Pharmaceuticals key executives?

    Vanda Pharmaceuticals's key executives are Michael F. Cola, Phaedra Chrousos and Anne Sempowski Ward.

  • How many employees does Vanda Pharmaceuticals have?

    Vanda Pharmaceuticals has 284 employees.

  • What is Vanda Pharmaceuticals revenue?

    Latest Vanda Pharmaceuticals annual revenue is $227.2 m.

  • What is Vanda Pharmaceuticals revenue per employee?

    Latest Vanda Pharmaceuticals revenue per employee is $800 k.

  • Who are Vanda Pharmaceuticals competitors?

    Competitors of Vanda Pharmaceuticals include Cyclacel Pharmaceuticals, Altogen Biosystems and ChemPartner.

  • Where is Vanda Pharmaceuticals headquarters?

    Vanda Pharmaceuticals headquarters is located at The Avenue, 2200 Pennsylvania Ave NW #300E, Washington.

  • Where are Vanda Pharmaceuticals offices?

    Vanda Pharmaceuticals has offices in Washington, Berlin and London.

  • How many offices does Vanda Pharmaceuticals have?

    Vanda Pharmaceuticals has 3 offices.